kbtbd12 Antibody

What is KBTBD12 and why is it studied?

KBTBD12 (Kelch Repeat and BTB POZ Domain Containing 12) is a protein containing both kelch repeat and BTB (POZ) domains. These structural motifs are involved in protein-protein interactions and are often found in proteins that participate in substrate recognition for ubiquitin ligase complexes. Researchers study KBTBD12 to understand its role in cellular processes, potentially including protein degradation pathways. Antibodies against KBTBD12 are essential tools for detecting, quantifying, and studying the localization and interactions of this protein in various experimental systems .

What types of KBTBD12 antibodies are currently available to researchers?

Currently, researchers have access to primarily polyclonal KBTBD12 antibodies raised in rabbits. These antibodies target different regions of the KBTBD12 protein, including N-terminal regions, C-terminal regions, and specific amino acid sequences (such as AA 487-536 and AA 139-188). Most available KBTBD12 antibodies are unconjugated, meaning they lack attached reporter molecules, and have been validated primarily for Western Blotting applications. The antibodies are typically supplied in liquid format with concentrations around 1 mg/mL and are most commonly preserved in buffer solutions containing sodium azide and sucrose .

What species reactivity can be expected from commercially available KBTBD12 antibodies?

Commercially available KBTBD12 antibodies demonstrate variable cross-species reactivity profiles. Based on sequence homology and experimental validation, many KBTBD12 antibodies show reactivity across multiple species with different percent identities. For example, the ABIN2791603 antibody demonstrates 100% reactivity with human KBTBD12 and varying degrees of predicted reactivity with other species: 93% for dog, guinea pig, horse, mouse, and rat samples; and 79% for cow and rabbit samples. This cross-reactivity information is crucial for researchers working with animal models to ensure their selected antibody will recognize the target protein in their experimental system .

What are the validated applications for KBTBD12 antibodies in research?

Currently, KBTBD12 antibodies have been primarily validated for Western Blotting (WB) applications. This technique allows researchers to detect and quantify KBTBD12 protein in complex biological samples after separation by gel electrophoresis. While Western Blotting is the confirmed application, researchers might explore other standard antibody applications such as immunohistochemistry, immunoprecipitation, or flow cytometry, though these would require additional validation. When designing experiments, researchers should begin with the manufacturer's recommended dilution ranges and optimize based on their specific experimental conditions and sample types. Validation data for applications beyond Western Blotting appears limited in the current literature, suggesting an opportunity for expanded characterization of these antibodies .

How should researchers design experiments to validate KBTBD12 antibody specificity?

To validate KBTBD12 antibody specificity, researchers should implement multiple complementary approaches:

• Positive and negative controls: Include samples with known KBTBD12 expression levels (high, low, and null)

• Blocking peptide competition: Pre-incubate the antibody with the immunogen peptide to confirm signal reduction

• Genetic validation: Use KBTBD12 knockout or knockdown samples alongside wild-type controls

• Cross-reactivity testing: Test against related proteins with similar domains

• Multiple antibody comparison: Use antibodies targeting different epitopes of KBTBD12 and compare detection patterns

For Western Blotting, researchers should confirm the detected protein appears at the expected molecular weight (~72 kDa for human KBTBD12) and displays consistent detection across multiple samples. Additionally, comparing the binding pattern with computational predictions of cross-reactivity (e.g., comparing the observed signal in mouse samples with the predicted 93% reactivity) can further validate specificity claims .

What approaches can resolve contradictory results when using KBTBD12 antibodies?

When researchers encounter contradictory results using KBTBD12 antibodies, several methodological approaches can help resolve discrepancies:

• Epitope analysis: Different antibodies target different regions of KBTBD12. Compare the epitope sequences of antibodies giving conflicting results to determine if protein modifications, splice variants, or protein-protein interactions might be affecting epitope accessibility.

• Alternative detection methods: Validate findings using orthogonal approaches such as mass spectrometry or RNA expression analysis (RT-PCR or RNA-seq).

• Binding mode analysis: Apply the biophysical model approach described in recent literature to identify if multiple binding modes are present that could explain contradictory results.

• Experimental condition optimization: Systematically adjust fixation methods, blocking solutions, incubation times and temperatures, and detection systems.

• Computational prediction: Use inference models that incorporate biophysical constraints to predict binding profiles and compare with experimental results.

This comprehensive approach leverages both experimental and computational methods to resolve contradictions and determine the true biological state of KBTBD12 in experimental systems .

How can researchers distinguish between specific binding and cross-reactivity with KBTBD12 antibodies?

Distinguishing between specific binding and cross-reactivity requires multifaceted validation approaches:

Researchers should also consider applying computational models as described in recent literature that can disentangle multiple binding modes and help identify contributions of off-target binding. These models associate each potential ligand with a distinct binding mode, enabling prediction of specific variants beyond experimentally observed sequences .

What factors influence KBTBD12 antibody cross-reactivity across species?

Several factors influence cross-reactivity of KBTBD12 antibodies across species:

• Epitope sequence conservation: The degree of amino acid sequence identity in the epitope region between species is the primary determinant of cross-reactivity. For KBTBD12 antibodies, there is substantial but varying conservation, with predicted reactivity ranging from 79% to 100% depending on the species.

• Protein structure and accessibility: Even with conserved sequences, differences in protein folding, post-translational modifications, or protein-protein interactions might affect epitope accessibility.

• Antibody production method: Polyclonal antibodies (like those available for KBTBD12) recognize multiple epitopes, potentially increasing cross-reactivity compared to monoclonal antibodies.

• Experimental conditions: Buffer components, detergents, and blocking agents can influence antibody binding specificity across species.

Researchers can leverage predicted cross-reactivity data (e.g., Cow: 79%, Dog: 93%, Guinea Pig: 93%, Horse: 93%, Human: 100%, Mouse: 93%, Rabbit: 79%, Rat: 93% for one antibody) to guide their experimental design when working with different model organisms .

What are the critical storage and handling requirements for KBTBD12 antibodies?

Proper storage and handling of KBTBD12 antibodies are essential for maintaining reactivity and specificity over time:

• Storage temperature: For long-term storage, maintain at -20°C in small aliquots to prevent repeated freeze-thaw cycles. For short-term use (up to 1 week), store at 2-8°C.

• Aliquoting: Upon receipt, divide the antibody solution into small single-use aliquots to minimize freeze-thaw cycles, which can denature antibodies and reduce activity.

• Safety considerations: KBTBD12 antibodies are typically supplied in buffer containing sodium azide (0.09% w/v), which is toxic and should be handled only by trained personnel with appropriate safety precautions.

• Buffer considerations: The antibodies are typically supplied in PBS buffer with 2% sucrose as a cryoprotectant. Avoid diluting the stock solution unless preparing working dilutions for immediate use.

• Concentration maintenance: Typical concentration is 1 mg/mL. When diluting for experiments, prepare fresh working solutions rather than storing diluted antibody.

Following these handling guidelines will help ensure consistent and reliable results when using KBTBD12 antibodies in research applications .

How should researchers optimize Western Blotting protocols for KBTBD12 detection?

Optimizing Western Blotting protocols for KBTBD12 detection requires systematic adjustment of several parameters:

• Sample preparation:

  • Include protease inhibitors to prevent degradation

  • Optimize lysis conditions (detergent type and concentration)

  • Ensure complete denaturation with appropriate heating time/temperature

• Gel electrophoresis:

  • Select appropriate gel percentage (typically 10-12% for KBTBD12)

  • Load sufficient protein (typically 20-40 μg of total protein)

• Transfer conditions:

  • Optimize transfer time and voltage for complete transfer of KBTBD12

  • Consider using PVDF membranes for higher protein binding capacity

• Blocking and antibody incubation:

  • Test different blocking agents (BSA vs. non-fat milk)

  • Determine optimal primary antibody dilution (starting from manufacturer's recommendation)

  • Optimize incubation time and temperature (overnight at 4°C often yields best results)

• Detection system:

  • Select appropriate secondary antibody compatible with detection method

  • Adjust exposure time for optimal signal-to-noise ratio

• Controls:

  • Include positive and negative controls in each experiment

  • Consider using loading controls to normalize KBTBD12 signal

Through systematic optimization of these parameters, researchers can achieve specific and sensitive detection of KBTBD12 protein in Western Blotting applications .

How can computational models improve KBTBD12 antibody specificity prediction?

Recent advances in computational modeling offer powerful approaches to predict and enhance KBTBD12 antibody specificity. These models incorporate biophysical constraints and machine learning techniques trained on experimental data from phage display selections. Key advantages include:

• Binding mode identification: Computational models can disentangle different binding modes associated with specific ligands, even when chemically similar.

• Cross-reactivity prediction: Models can predict potential cross-reactivity with related proteins or across species without requiring exhaustive experimental testing.

• Specificity profile customization: Researchers can design antibodies with tailored specificity profiles, either highly specific for a particular target or cross-specific for multiple desired targets.

• Sequence-function relationship: Models reveal how amino acid sequences relate to binding properties, guiding rational mutation strategies.

• Experimental bias mitigation: Computational approaches can help identify and correct for biases in experimental selection procedures.

These computational approaches have been validated experimentally, demonstrating the ability to design novel antibody sequences with customized specificity profiles beyond those observed in initial libraries, which could be applied to developing improved KBTBD12 antibodies .

What are the advanced methodologies for designing highly specific KBTBD12 antibodies?

Designing highly specific KBTBD12 antibodies can be achieved through an integrated experimental-computational approach:

• Phage display selection strategy:

  • Conduct parallel selections against KBTBD12 and closely related proteins

  • Implement counter-selection steps to deplete cross-reactive antibodies

  • Perform multiple rounds of selection with increasing stringency

• High-throughput sequencing analysis:

  • Sequence antibody populations before and after selection

  • Track enrichment patterns across multiple selection conditions

  • Identify sequence motifs associated with specific binding

• Biophysically informed computational modeling:

  • Develop models that distinguish multiple binding modes

  • Parameterize binding energies using neural networks

  • Optimize model parameters to capture experimentally observed enrichment patterns

• De novo antibody design:

  • For specific binders: Minimize binding energy for KBTBD12 while maximizing energy for off-targets

  • For cross-specific binders: Jointly minimize binding energy for desired targets

  • Generate novel sequences not present in the initial library but with predicted specificity profiles

• Experimental validation:

  • Test designed antibodies against KBTBD12 and related proteins

  • Confirm specificity through multiple orthogonal methods

  • Refine computational models based on validation results

This integrated approach leverages the strengths of both experimental selection and computational prediction to generate antibodies with unprecedented specificity for KBTBD12 .